{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:08:50Z","timestamp":1791454130569,"version":"4.3.3"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Hypercalcemia complicates the course of 10%\u201330% of all patients with malignancies and can be a sign of very poor prognosis and advanced malignancy. Prompt recognition of the nonspecific signs and symptoms of hypercalcemia and institution of therapy can be lifesaving, affording the opportunity to address the underlying etiology. The mechanisms of malignancy-associated hypercalcemia generally fall into three categories: humoral hypercalcemia due to secreted factors (such as parathyroid-related hormone), local osteolysis due to tumor invasion of bone, and absorptive hypercalcemia due to excess vitamin D produced by malignancies. The mainstays of therapy for hypercalcemia are aggressive intravenous volume expansion with saline, bisphosphonate therapy, and perhaps loop diuretics. Adjunctive therapy may include calcitonin and corticosteroids. In refractory cases, gallium nitrate and perhaps denosumab are alternatives. In patients presenting with severe AKI, hemodialysis with a low-calcium bath can be effective. In most cases, therapy normalizes calcium levels and allows for palliation or curative therapy of the malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.02470312","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T20:25:39Z","timestamp":1344716739000},"page":"1722-1729","source":"Crossref","is-referenced-by-count":137,"title":["Onco-Nephrology"],"prefix":"10.2215","volume":"7","author":[{"given":"Mitchell H.","family":"Rosner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Dalkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20230811","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2141.2010.08173.x","article-title":"Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders","volume":"149","author":"Sargent","year":"2010","journal-title":"Br J Haematol"},{"key":"R2-25-20230811","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-25-20230811","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","article-title":"Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients","volume":"112","author":"Ralston","year":"1990","journal-title":"Ann Intern Med"},{"key":"R4-25-20230811","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archsurg.1980.01380060012004","article-title":"Incidence of hypercalcemia and malignant neoplasm","volume":"115","author":"Burt","year":"1980","journal-title":"Arch Surg"},{"key":"R5-25-20230811","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1097-0142(19930215)71:4<1309::AID-CNCR2820710423>3.0.CO;2-M","article-title":"Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center","volume":"71","author":"Vassilopoulou-Sellin","year":"1993","journal-title":"Cancer"},{"key":"R6-25-20230811","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0025-7125(16)30085-2","article-title":"Hypercalcemic crisis","volume":"79","author":"Edelson","year":"1995","journal-title":"Med Clin North Am"},{"key":"R7-25-20230811","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/ndt\/gfn747","article-title":"The impact of the assay for measuring albumin on corrected (\u2018adjusted\u2019) calcium concentrations","volume":"24","author":"Labriola","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R8-25-20230811","first-page":"49","article-title":"Estimation of ionized calcium, total calcium and albumin corrected calcium for the diagnosis of hypercalcaemia of malignancy","volume":"16","author":"Ijaz","year":"2006","journal-title":"J Coll Physicians Surg Pak"},{"key":"R9-25-20230811","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/pgmj.67.786.350","article-title":"Is the routine measurement of ionized calcium worthwhile in patients with cancer?","volume":"67","author":"Riancho","year":"1991","journal-title":"Postgrad Med J"},{"key":"R10-25-20230811","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/JOE-11-0212","article-title":"The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption","volume":"211","author":"Mellis","year":"2011","journal-title":"J Endocrinol"},{"key":"R11-25-20230811","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R12-25-20230811","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"R13-25-20230811","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"key":"R14-25-20230811","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1073\/pnas.89.7.2732","article-title":"Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium","volume":"89","author":"Abou-Samra","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"R15-25-20230811","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10555-007-9081-z","article-title":"Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone","volume":"26","author":"Sone","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"R16-25-20230811","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1210\/jcem-73-6-1309","article-title":"Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer","volume":"73","author":"Grill","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-25-20230811","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2005.08.020","article-title":"Parathyroid hormone-related protein in human renal cell carcinoma","volume":"240","author":"Sourbier","year":"2006","journal-title":"Cancer Lett"},{"key":"R18-25-20230811","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jcem-68-5-976","article-title":"Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia","volume":"68","author":"Yoshimoto","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-25-20230811","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1210\/jcem.83.8.5025","article-title":"Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland","volume":"83","author":"Iguchi","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-25-20230811","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJM199011083231907","article-title":"Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone","volume":"323","author":"Nussbaum","year":"1990","journal-title":"N Engl J Med"},{"key":"R21-25-20230811","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2781","article-title":"Breast cancer metastasis to the bone: Mechanisms of bone loss","volume":"12","author":"Chen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"R22-25-20230811","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MED.0b013e32834b4401","article-title":"Mechanisms and treatment of hypercalcemia of malignancy","volume":"18","author":"Clines","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R23-25-20230811","first-page":"567","article-title":"Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma","volume":"89","author":"Abildgaard","year":"2004","journal-title":"Haematologica"},{"key":"R24-25-20230811","first-page":"801","article-title":"Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy","volume":"76","author":"Schilling","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-25-20230811","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood.V82.5.1383.1383","article-title":"Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphomas","volume":"82","author":"Seymour","year":"1993","journal-title":"Blood"},{"key":"R26-25-20230811","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0925-5710(96)00578-6","article-title":"Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management","volume":"66","author":"Hatake","year":"1997","journal-title":"Int J Hematol"},{"key":"R27-25-20230811","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/jsre.1996.0080","article-title":"Renovascular responses to high and low perfusate calcium steady-state experiments in the isolated perfused rat kidney with baseline vascular tone","volume":"61","author":"Castelli","year":"1996","journal-title":"J Surg Res"},{"key":"R28-25-20230811","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00041552-199601000-00009","article-title":"The scent of an ion: Calcium-sensing and its roles in health and disease","volume":"5","author":"Hebert","year":"1996","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R29-25-20230811","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.semnephrol.2006.03.004","article-title":"Acquired nephrogenic diabetes insipidus","volume":"26","author":"Khanna","year":"2006","journal-title":"Semin Nephrol"},{"key":"R30-25-20230811","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(83)90231-3","article-title":"Comparison of intravenous (3-amino-1-hydroxypropylidene)-1-1-bisphosphonate and volume repletion in tumour-induced hypercalcemia","volume":"2","author":"Sleeboom","year":"1983","journal-title":"Lancet"},{"key":"R31-25-20230811","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.hoc.2010.03.007","article-title":"Electrolyte complications of malignancy","volume":"24","author":"Kacprowicz","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"R32-25-20230811","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: Furosemide for hypercalcemia: An unproven yet common practice","volume":"149","author":"LeGrand","year":"2008","journal-title":"Ann Intern Med"},{"key":"R33-25-20230811","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1600-0773.1969.tb00495.x","article-title":"Magnesium and calcium metabolism during prolonged furosemide (Lasix) administration to normal rats","volume":"27","author":"Nielsen","year":"1969","journal-title":"Acta Pharmacol Toxicol (Copenh"},{"key":"R34-25-20230811","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/bmj.1.5746.437","article-title":"Effect of frusemide administration on calcium excretion","volume":"1","author":"Toft","year":"1971","journal-title":"BMJ"},{"key":"R35-25-20230811","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"R36-25-20230811","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"R37-25-20230811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: From the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"R38-25-20230811","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","article-title":"Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis","volume":"33","author":"Amin","year":"1992","journal-title":"J Lipid Res"},{"key":"R39-25-20230811","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"R40-25-20230811","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s002239900606","article-title":"Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts","volume":"64","author":"Hiroi-Furuya","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"R41-25-20230811","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1054\/bjoc.2000.1679","article-title":"Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line","volume":"84","author":"Mackie","year":"2001","journal-title":"Br J Cancer"},{"key":"R42-25-20230811","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/bjc.1995.502","article-title":"A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy","volume":"72","author":"Purohit","year":"1995","journal-title":"Br J Cancer"},{"key":"R43-25-20230811","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.1999.14.9.1557","article-title":"A dose-finding study of zoledronate in hypercalcemic cancer patients","volume":"14","author":"Body","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R44-25-20230811","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1996.14.1.268","article-title":"Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy","volume":"14","author":"Pecherstorfer","year":"1996","journal-title":"J Clin Oncol"},{"key":"R45-25-20230811","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(93)90282-T","article-title":"Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages","volume":"95","author":"Nussbaum","year":"1993","journal-title":"Am J Med"},{"key":"R46-25-20230811","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/pgmj.68.800.434","article-title":"Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia","volume":"68","author":"Dodwell","year":"1992","journal-title":"Postgrad Med J"},{"key":"R47-25-20230811","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/0140-6736(93)90756-7","article-title":"Parathyroid hormone-related protein and response to pamidronate in tumor-induced hypercalcemia","volume":"341","author":"Gurney","year":"1993","journal-title":"Lancet"},{"key":"R48-25-20230811","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/bjc.1994.270","article-title":"Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein","volume":"70","author":"Walls","year":"1994","journal-title":"Br J Cancer"},{"key":"R49-25-20230811","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"R50-25-20230811","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00520-003-0477-1","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: A randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer","year":"2003","journal-title":"Support Care Cancer"},{"key":"R51-25-20230811","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcaemia of malignancy","volume":"21","author":"Zojer","year":"1999","journal-title":"Drug Saf"},{"key":"R52-25-20230811","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R53-25-20230811","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x","article-title":"Podocyte injury associated glomerulopathies induced by pamidronate","volume":"65","author":"Barri","year":"2004","journal-title":"Kidney Int"},{"key":"R54-25-20230811","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","article-title":"Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma","volume":"119","author":"Desikan","year":"2002","journal-title":"Br J Haematol"},{"key":"R55-25-20230811","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"Markowitz","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R56-25-20230811","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfm209","article-title":"Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient","volume":"22","author":"Bodmer","year":"2007","journal-title":"Dial Transplant"},{"key":"R57-25-20230811","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"R58-25-20230811","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"R59-25-20230811","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"R60-25-20230811","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"R61-25-20230811","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"R62-25-20230811","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R63-25-20230811","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2354.2005.00641.x","article-title":"Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: Phase III trial results","volume":"15","author":"Body","year":"2006","journal-title":"Eur J Cancer Care (Engl"},{"key":"R64-25-20230811","first-page":"S45","article-title":"Renal safety of ibandronate in multiple myeloma patients with renal deterioration","volume":"31","author":"Bergner","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R65-25-20230811","first-page":"268","article-title":"Bisphosphonates and avascular necrosis of the jaws","volume":"48","author":"Carter","year":"2003","journal-title":"Aust Dent J"},{"key":"R66-25-20230811","doi-asserted-by":"crossref","first-page":"692","DOI":"10.14219\/jada.archive.2007.0242","article-title":"For the dental patient. Osteoporosis medications and the risk of developing jaw complications","volume":"138","author":"Hellstein","year":"2007","journal-title":"J Am Dent Assoc"},{"key":"R67-25-20230811","first-page":"1096","article-title":"Bisphosphonate-associated mandibular osteonecrosis","volume":"27","author":"Carneiro","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"key":"R69-25-20230811","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF02556640","article-title":"Effect of gallium on bone mineral properties","volume":"43","author":"Repo","year":"1988","journal-title":"Calcif Tissue Int"},{"key":"R70-25-20230811","first-page":"21","article-title":"Studies on the mechanism of action of gallium nitrate","volume":"18","author":"Bockman","year":"1991","journal-title":"Semin Oncol"},{"key":"R71-25-20230811","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI111353","article-title":"Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia","volume":"73","author":"Warrell","year":"1984","journal-title":"J Clin Invest"},{"key":"R72-25-20230811","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0169-6009(90)90106-P","article-title":"Gallium inhibits bone resorption by a direct effect on osteoclasts","volume":"8","author":"Hall","year":"1990","journal-title":"Bone Miner"},{"key":"R73-25-20230811","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00130404-200601000-00009","article-title":"Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia","volume":"12","author":"Cvitkovic","year":"2006","journal-title":"Cancer J"},{"key":"R74-25-20230811","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.1991.9.8.1467","article-title":"A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia","volume":"9","author":"Warrell","year":"1991","journal-title":"J Clin Oncol"},{"key":"R75-25-20230811","doi-asserted-by":"crossref","first-page":"669","DOI":"10.7326\/0003-4819-108-5-669","article-title":"Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin","volume":"108","author":"Warrell","year":"1988","journal-title":"Ann Intern Med"},{"key":"R76-25-20230811","first-page":"33","article-title":"Molecular physiology and pharmacology of calcitonin","volume":"52","author":"Huang","year":"2006","journal-title":"Cell Mol Biol (Noisy-le-grand"},{"key":"R77-25-20230811","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/10606820213681","article-title":"Molecular pharmacology of the calcitonin receptor","volume":"8","author":"Purdue","year":"2002","journal-title":"Receptors Channels"},{"key":"R78-25-20230811","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1093\/ajhp\/58.suppl_3.S8","article-title":"Conventional treatment of hypercalcemia of malignancy","volume":"58","author":"Davidson","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"R79-25-20230811","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.PCC.0000059423.62268.02","article-title":"Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin","volume":"4","author":"Mathur","year":"2003","journal-title":"Crit Care Med"},{"key":"R80-25-20230811","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJM199204303261806","article-title":"Management of acute hypercalcemia","volume":"326","author":"Bilezikian","year":"1992","journal-title":"N Engl J Med"},{"key":"R81-25-20230811","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1241821","article-title":"Hypercalcemia in cancer patients: Pathobiology and management","volume":"42","author":"Santarpia","year":"2010","journal-title":"Horm Metab Res"},{"key":"R82-25-20230811","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ki.1993.92","article-title":"Calcium kinetics and the long-term effects of lowering dialysate calcium concentration","volume":"43","author":"Argil\u00e9s","year":"1993","journal-title":"Kidney Int"},{"key":"R83-25-20230811","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s001340050562","article-title":"Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia","volume":"24","author":"Sr\u00e1mek","year":"1998","journal-title":"Intensive Care Med"},{"key":"R84-25-20230811","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MAT.0b013e31817dc3be","article-title":"Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation","volume":"54","author":"Kindgen-Milles","year":"2008","journal-title":"ASAIO J"},{"key":"R85-25-20230811","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1634\/theoncologist.2010-0154","article-title":"The role of RANK-ligand inhibition in cancer: the story of denosumab","volume":"16","author":"Castellano","year":"2011","journal-title":"Oncologist"},{"key":"R87-25-20230811","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"R88-25-20230811","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"R89-25-20230811","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"R90-25-20230811","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201210000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:26Z","timestamp":1786369346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201210000-00025"}},"subtitle":["The Pathophysiology and Treatment of Malignancy-Associated Hypercalcemia"],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02470312","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}